North America Adalimumab Market is Expected to Reach USD 21,956.98 Million & Grow at a CAGR of 4.9% Forecast to 2021-2028
North America Adalimumab market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 4.9% in the forecast period of 2020 to 2027 and is expected to reach USD 21,956.98 million by 2027. Presence of reimbursement and rise in the prevalence of rheumatoid arthritis are the major drivers which propelled the demand of the market in the forecast period mentioned above.
Adalimumab is one of the monoclonal antibodies and is used for the treatment of certain autoimmune diseases involving rheumatoid arthritis and crohn’s diseases among others. Adalimumab is an anti- TNF drug indicated for the treatment of inflammatory symptoms. The biologic of adalimumab is humira and various biosimilar drugs of humira are also available which involves exemptia, hyrimoz, cyltezo and hulio among several others. Adalimumab works by binding to the TNF factor-alpha which reduces the chances of the inflammatory response to autoimmune diseases.
Get a Sample Copy of the Report to comprehend the construction of the total report (Including Full TOC, Table, and Figures): https://www.databridgemarketresearch.com/request-a-sample/?dbmr=north-america-adalimumab-market
Major Market Key Competitors:
- AbbVie Inc.
- Amgen (Europe) GmbH (A Subsidiary of Amgen Inc.)
- CELLTRION INC.
- Samsung Bioepis (a subsidiary of Samsung Biologics)
- Coherus BioSciences
- Innovent Biologics, Inc.
- Mylan N.V.
- Zydus Cadila
- Hetero Biopharma Ltd.
- Fresenius Kabi Deutschland GmbH (A Subsidiary of Fresenius Kabi AG)
- Sandoz International GmbH (A Subsidiairy of Sandoz (A Division of Novartis AG))
- Pfizer Inc.
- Boehringer Ingelheim International GmbH
Adalimumab Market Scope and Market Size
Adalimumab market is segmented on the based on the basis of indication, type, dosage strength, drug type, route of administration, population type, end – user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of indication, the adalimumab market the market is segmented into rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, chronic plaque psoriasis, crohn’s disease, ulcerative colitis, juvenile idiopathic arthritis, hidradenitis suppurativa, non-infectious intermediate and others. In 2020, rheumatoid arthritis segment is dominating the market because of increasing population of patients suffering from rheumatoid arthritis. Along with this increasing geriatric population is another factor responsible for accelerating the growth of rheumatoid arthritis segment.
- On the basis of type, the adalimumab market is segmented into biologics and biosimilars. In 2020, biologics segment is dominating the market because of the wide distribution network of Humira, a biologic drug.
- On the basis of dosage strength, the adalimumab market is segmented into 40mg/0.4ml, 80mg/0.8ml, 20mg/0.4ml, 10mg/0.1ml, and others. In 2020, 40mg/0.4ml is dominating the market because majority of population or patients are prescribed by the 40mg/0.4ml of drug dosage in order to achieve first line of therapy for inflammatory diseases.
- On the basis of drug type, the adalimumab market is segmented into branded and generics. In 2020, branded segment is dominating the market because patients are more assured with the branded product; moreover the branded Humira is preferred by healthcare professionals all over the world.
- On the basis of route of administration, the adalimumab market is segmented into parenteral, and oral. In 2020, parenteral segment is dominating the market because adalimumab is only b given through SC route so as to induce slow and effective long term systemic effect.
- On the basis of population type, the adalimumab market is segmented into adults, children. In 2020, adults segment is dominating the market because adult populations have weak immune system and thus are more prone to inflammatory diseases.
- On the basis of end user, the adalimumab market is segmented into hospitals, specialty clinics, home healthcare, and others. In 2020, hospitals segment is dominating the market because of the presence of skilled professionals and best insurance coverage policies.
- On the basis of distribution channel, the adalimumab market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, direct tenders, others. In 2020, hospital pharmacies dominating the market because adalimumab is only prescribed by the doctors, so most of the patients visited to hospital procures adalimumab from nearby hospital pharmacies.
Get the Latest TOC Of This Report @ https://www.databridgemarketresearch.com/toc/?dbmr=north-america-adalimumab-market
Adalimumab Market Country Level Analysis
The adalimumab market is analyzed and market size information is provided by country, indication, type, dosage strength, drug type, route of administration, population type, and end-user and distribution channel as referenced above.
The countries covered in the adalimumab market report are the U.S., Canada, and Mexico.
The U.S. is dominating the market in North America because Humira (Adalimumab) is one of the bestselling drugs in the market
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Increasing Geriatric Population and Increasing Number of Contract Research Organizations are Boosting the Market Growth of Adalimumab
Adalimumab market also provides you with detailed market analysis for every country growth in Adalimumab industry with Adalimumab drugs sales, impact of advancement in the Adalimumab technology and changes in regulatory scenarios with their support for the Adalimumab market. The data is available for historic period 2010 to 2018.
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, and Italy)
Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)
South America (Brazil, Argentina, Colombia, etc.)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)
LIST OF FIGURES
FIGURE 1 NORTH AMERICA ADALIMUMAB MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA ADALIMUMAB MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA ADALIMUMAB MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA ADALIMUMAB MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA ADALIMUMAB MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA ADALIMUMAB MARKET: MULTIVARIATE MODELLING
FIGURE 7 NORTH AMERICA ADALIMUMAB MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 NORTH AMERICA ADALIMUMAB MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA ADALIMUMAB MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA IS EXPECTED TO DOMINATE AND ASIA-PACIFIC IS THE HIGHEST GROWING REGION IN NORTH AMERICA ADALIMUMAB MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 11 RISE IN THE PREVALENCE OF RHEUMATOID ARTHRITIS AND INCREASING GERIATRIC POPULATION IS DRIVING THE NORTH AMERICA ADALIMUMAB MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 12 RHEUMATOID ARTHRITIS IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA ADALIMUMAB MARKET IN 2020 & 2027
FIGURE 13 NORTH AMERICA IS THE FASTEST GROWING MARKET IN NORTH AMERICA ADALIMUMAB MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA ADALIMUMAB MARKET
FIGURE 15 MARKET GROWTH IN CLINICAL CRO (IN USD MILLIONS)
FIGURE 16 FUNCTION OF CRO
FIGURE 17 HEALTHCARE EXPENDITURE IN 2016 AND 2019
FIGURE 18 NORTH AMERICA ADALIMUMAB MARKET: BY INDICATION, 2019
FIGURE 19 NORTH AMERICA ADALIMUMAB MARKET: BY INDICATION, 2019-2027 (USD MILLION)
FIGURE 20 NORTH AMERICA ADALIMUMAB MARKET: BY INDICATION, CAGR (2020-2027)
FIGURE 21 NORTH AMERICA ADALIMUMAB MARKET: BY INDICATION, LIFELINE CURVE
FIGURE 22 NORTH AMERICA ADALIMUMAB MARKET: BY TYPE, 2019
FIGURE 23 NORTH AMERICA ADALIMUMAB MARKET: BY TYPE 2019-2027 (USD MILLION)
FIGURE 24 NORTH AMERICA ADALIMUMAB MARKET: BY TYPE, CAGR (2020-2027)
FIGURE 25 NORTH AMERICA ADALIMUMAB MARKET: BY TYPE, LIFELINE CURVE
Get More Information on this Research Report: https://www.databridgemarketresearch.com/reports/north-america-adalimumab-market
– Market Size and Forecast by Revenue | 2021−2028
– Market Dynamics – Leading patterns, development drivers, limitations, and venture openings
– Market Segmentation – An itemized examination by item, by types, end-client, applications, fragments, and geology
– Competitive Landscape – Top key sellers and other conspicuous vendorsInquire
Research Methodology: North America Adalimumab Market
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include vendor positioning grid, market time line analysis, market overview and guide, company positioning grid, company market share analysis, standards of measurement, top to bottom analysis and vendor share analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
- Demand Side: Manufacturer, Healthcare Industry, Immunologists, Scientists, Research Laboratories
- Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.
- Global Biosimilar Market – Industry Trends and Forecast to 2026
- Global Adalimumab Biosimilar Market – Industry Trends and Forecast to 2027
About Data Bridge Market Research
An absolute way to forecast what the future holds is to comprehend the trend today!
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to complex business challenges and initiates an effortless decision-making process.
Data Bridge is adept at creating satisfied clients who rely on our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
- The Wire Times